Ilaria Chiarugi

Dr. Ilaria Chiarugi


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ICIlaria Chiarugi
Ilaria Chiarugi
DBDiletta Biagi
Diletta Biagi
PNPaolo Nencioni
Paolo Nencioni
Francesca MaestrelliFrancesca Maestrelli
Francesca Maestrelli
MVMaurizio Valleri
Maurizio Valleri
Paola Angela MuraPaola Angela Mura
Paola Angela Mura
Orally disintegrating granules (ODGs) are a pharmaceutical form commonly used for the administration of NSAIDs because of their easy assumption and fast dispersion. The development of ODGs is not easy for drugs like dexketoprofen trometamol (DXKT), which have a bitter and burning taste. In this work, high-shear coating (HSC) was used as an innovative technique for DKXT taste masking. This study focused on coating DXKT granules using the HSC technique with a low-melting lipid excipient, glyceryl distearate (GDS). The HSC technique allowed for the coating to be developed through the thermal rise resulting from the friction generated by the granules movement inside the equipment, causing the coating excipient to soften. The design of the experiment was used to find the best experimental coating conditions in order to gain effective taste masking by suitably reducing the amount of drug released in the oral cavity. The influence of the granule dimensions was also investigated. Coating effectiveness was evaluated using a simulated saliva dissolution test. It was found that low impeller speed (300 rpm) and a 20% coating excipient were effective in suitably reducing the drug dissolution rate and then in taste masking. The coated granules were characterized for their morphology and solid-state properties by SEM, BET, XRPD, DSC, and NIR analyses. A human taste panel test confirmed the masking of DXKT taste in the selected batch granules.

21 February 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ICIlaria Chiarugi
Ilaria Chiarugi
Francesca MaestrelliFrancesca Maestrelli
Francesca Maestrelli
GPGiulia Piomboni
Giulia Piomboni
Sandra RistoriSandra Ristori
Sandra Ristori
ABAnna Rita Bilia
Anna Rita Bilia
Gene delivery/administration and, in particular, small interfering RNA (siRNA) delivery represent a therapeutic challenge, though very effective carriers have yet to be identified. Cyclodextrins (CDs) are cyclic oligosaccharides with unique host–guest inclusion capabilities, widely recognized in the pharmaceutical field for their ability to enhance drug solubility and bioavailability. Their excellent biocompatibility and chemical versatility make them powerful building blocks for the design of supramolecular nanovectors (NVs). Thanks to their facility of functionalization, CDs are highly versatile and have found numerous applications across various fields. In this context, CD-based NVs are currently explored as non-viral agents to transport and release siRNA. Recent studies suggest that self-assembled NVs based on CDs can improve the transfection and safety of siRNA delivery. This review provides a comprehensive overview of the most recent advances in the design of NVs based on CDs and their use for siRNA delivery, discussing the role played by structural differences and chemical functionalization in the context of encapsulation and release.

29 March 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
ICIlaria Chiarugi
Ilaria Chiarugi
Francesca MaestrelliFrancesca Maestrelli
Francesca Maestrelli
MMMilo Malanga
Milo Malanga
GPGiulia Piomboni
Giulia Piomboni
LFLorena Valverde Fraga
Lorena Valverde Fraga
NCNoemi Csaba
Noemi Csaba
Gene therapy represents a promising strategy for the treatment of severe diseases through delivery of genetic material into target cells. Its clinical translation, however, remains limited by the need for safe and efficient vectors. β-Cyclodextrins (β-CDs), owing to their biocompatibility and structural tunability, represent an attractive platform. In this study, three novel cationic β-CD derivatives (CD1, CD2, and CD3), functionalized with amino groups and different lipophilic chains, were evaluated. Preformulation studies were conducted to optimize the composition and preparation of β-CD-based nanovectors (NVs), which were subsequently complexed with a GFP-encoding plasmid (pGFP). Sodium hyaluronate (HA) and polysialic acid (PSA), were incorporated at 10% w/w, to enhance loading capacity and biocompatibility. Physico-chemical characterization included size, polydispersity index (PdI), and zeta potential. Further insights concerning the architecture of NVs were obtained by TEM, Cryo-EM, and synchrotron SAXS, which indicated a hierarchical arrangement in the structure of the complexes, while electrophoresis verified efficient nucleic acid binding. Stability was assessed at 4 °C for one week and in culture medium for 24 h. MTT test was performed in HeLa cells and transfection efficiency was analysed by flow cytometry and fluorescence microscopy. NVs were then complexed with GFP-targeting-siRNA (N/P = 10), and silencing efficiency was assessed in HeLa-GFP cells. All formulations displayed suitable size (<200 nm) and PdI (<0.3). CD1 showed the highest biopharmaceutical performance, achieving GFP expression and silencing efficiency comparable to commercial Lipofectamine. Overall, CD1 emerged as the most promising candidate, supporting its potential as an effective and biocompatible NVs for gene delivery.

24 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ICIlaria Chiarugi
Ilaria Chiarugi
Francesca MaestrelliFrancesca Maestrelli
Francesca Maestrelli
GPGiulia Piomboni
Giulia Piomboni
Sandra RistoriSandra Ristori
Sandra Ristori
ABAnna Rita Bilia
Anna Rita Bilia
Gene delivery/administration and, in particular, small interfering RNA (siRNA) delivery represents a therapeutic challenge and very effective carriers have yet to be identified. Cyclodextrins (CDs) are cyclic oligosaccharides with unique host–guest inclusion capabilities, widely recognized in the pharmaceutical field for their ability to enhance drug solubility and bioavailability. Their excellent biocompatibility and chemical ver-satility make them powerful building blocks for the design of supramolecular nano-vectors (NVs). Thanks to their facility of functionalization, CDs are highly versatile and have found numerous applications across various fields. In this contest CD based NVs are currently explored as non-viral agents to transport and release siRNA. Recent studies suggest that self-assembled NVs based on CDs can improve the transfection and safety of siRNA delivery systems. This review provides a comprehensive overview of the most recent advances in the design of NVs based on CDs and their use for delivery of siRNA, discussing the ins and outs of structural differences and chemical functionalization.